Darinaparsin: A novel organic arsenical with promising anticancer activity

Expert Opinion on Investigational Drugs

Volumn 18, Issue 11, 2009, Pages 1727-1734

  Mann, Koren K ^a   Wallner, Barbara ^b   Lossos, Izidore S ^c   Miller Jr , Wilson H ^a  

^a MCGILL UNIVERSITY   (Canada)

^b Ziopharm Oncology   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Apoptosis; Arsenic; Darinaparsin; Lymphoma; Mitochondria; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ASCORBIC ACID; BORTEZOMIB; BUTHIONINE SULFOXIMINE; CYCLOSPORIN A; DARINAPARSIN; DEXAMETHASONE; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE; IRINOTECAN; MELARSOPROL; MELPHALAN; OXALIPLATIN; REACTIVE OXYGEN METABOLITE; SORAFENIB; TROLOX C; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATAXIA; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL DEATH; CENTRAL NERVOUS SYSTEM TUMOR; CHEMISTRY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CARCINOMA; CONFUSION; CONGESTIVE HEART FAILURE; COORDINATION; CYTOTOXICITY; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG UPTAKE; DYSARTHRIA; DYSPNEA; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HEART ATRIUM FIBRILLATION; HUMAN; IN VIVO STUDY; KIDNEY CANCER; LEUKEMIA; LEUKEMIA CELL; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHOMA; MELANOMA; MENTAL HEALTH; MITOCHONDRION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; PROSTATE CANCER; QT PROLONGATION; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; ARSENICALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; GLUTATHIONE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 73849095467     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903282759     Document Type: Review

References (44)

1. Waxman S, Anderson KC. History of the development of arsenic derivatives in cancer therapy. Oncologist 2001;6(Suppl 2):3-10
2. Antman KH. Introduction: the history of arsenic trioxide in cancer therapy. Oncologist 2001;6(Suppl 2):1-2
3. Tseng CH. Metabolism of inorganic arsenic and non-cancerous health hazards associated with chronic exposure in humans. J Environ Biol 2007;28(2 Suppl):349-357
4. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113(9):1875-1891
5. Tallman MS. The expanding role of arsenic in acute promyelocytic leukemia. Semin Hematol 2008;45(3 Suppl 2):S25-9
6. Hermine O, Dombret H, Poupon J, et al. Phase II trial of arsenic trioxide and alpha interferon in patients with relapsed/refractory adult T-cell leukemia/lymphoma. Hematol J 2004;5(2):130-134
7. Hussein MA. Trials of arsenic trioxide in multiple myeloma. Cancer Control 2003;10(5):370-374
8. List A, Beran M, DiPersio J, et al. Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003;17(8):1499-1507
9. Niu C, Yan H, Yu T, et al. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999;94(10):3315-3324
10. Konig A, Wrazel L, Warrell RP Jr, et al. Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines. Blood 1997;90(2):562-570
11. Soignet SL, Tong WP, Hirschfeld S, Warrell RP Jr. Clinical study of an organic arsenical, melarsoprol, in patients with advanced leukemia. Cancer Chemother Pharmacol 1999;44(5):417-421
12. Sahara N, Takeshita A, Kobayashi M, et al. Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway. Leuk Lymphoma 2004;45(5):987-995
13. Don AS, Kisker O, Dilda P, et al. A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. Cancer Cell 2003;3(5):497-509
14. Golemovic M, Quintas-Cardama A, Manshouri T, et al. MER1, a novel organic arsenic derivative, has potent PML-RARalpha- independent cytotoxic activity against leukemia cells. Invest New Drugs 2009; published online 26 May:doi:10.1007/s10637-009-9267-z
15. Quintas-Cardama A, Verstovsek S, Freireich E, et al. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem 2008;8(8):904-909
16. Kumagai Y, Sumi D. Arsenic: signal transduction, transcription factor, and biotransformation involved in cellular response and toxicity. Annu Rev Pharmacol Toxicol 2007;47:243-262
17. Chen GQ, Zhou L, Styblo M, et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res 2003;63(8):1853-1859
18. Ferrario D, Croera C, Brustio R, et al. Toxicity of inorganic arsenic and its metabolites on haematopoietic progenitors "in vitro": comparison between species and sexes. Toxicology 2008;249(2-3):102-108
19. Dopp E, Hartmann LM, Florea AM, et al. Uptake of inorganic and organic derivatives of arsenic associated with induced cytotoxic and genotoxic effects in Chinese hamster ovary (CHO) cells. Toxicol Appl Pharmacol 2004;201(2):156-165
20. Piatek K, Schwerdtle T, Hartwig A, Bal W. Monomethylarsonous acid destroys a tetrathiolate zinc finger much more efficiently than inorganic arsenite: mechanistic considerations and consequences for DNA repair inhibition. Chem Res Toxicol 2008;21(3):600-606
21. Matulis SM, Morales AA, Yehiayan L, et al. Darinaparsin induces a unique cellular response and is active in an arsenic trioxide-resistant myeloma cell line. Mol Cancer Ther 2009;8(5):1197-1206
22. Boise LH, Morales AA, Croutch C, et al. S-dimethylarsinoglutatione (ZIO-101): a novel organic arsenic with a unique gene expression profile in myeloma [abstract]. American Association for Cancer Research Annual Meeting: Proceedings 2007;48:abstract nr 4827
23. Diaz Z, Mann KK, Marcoux S, et al. A novel arsenical has antitumor activity toward As2O3-resistant and MRP1/ABCC1-overexpressing cell lines. Leukemia 2008;22(10):1853-1863
24. Wang ZG, Rivi R, Delva L, et al. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 1998;92(5):1497-1504
25. Chou WC, Jie C, Kenedy AA, et al. Role of NADPH oxidase in arsenic-induced reactive oxygen species formation and cytotoxicity in myeloid leukemia cells. Proc Natl Acad Sci USA 2004;101(13):4578-4583
26. Woo SH, Park IC, Park MJ, et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol 2002;21(1):57-63
27. Manshouri T, Subbarao VK, Ashoori F, et al. Comparison of uptake and iIntracellular induced structural changes of arsenic trioxide, an inorganic compound, and organic arsenic derivative S-dimethylarsinoglutathione (SGLU; ZIO-101) in NB4 Acute Promyelocytic leukemia (APL) cells [abstract]. Blood 2005;106:abstract nr 4446
28. Manshouri T, Freireich E, Zingaro R, et al. Organic and inorganic arsenics operate by different biochemical pathways to induce apoptosis in cancer cells. Eur J Cancer Suppl 2005;4(12):133
29. Cheng X, Taghi M, Huang P, et al. Mechanisms of increased reactive oxygen species (ROS) generation induced by organic arsenic derivative S-dimethylarsinoglutathione (SGLU; ZIO-101) [abstract]. Blood 2005;106:abstract nr 4445
30. Heyfets A, Flescher E. A new organic arsenic derivate, darinaparsin, acts directly on isolated human cancer cell mitochondria. manuscript submitted
31. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341(Pt 2):233-249
32. Dai J, Weinberg RS, Waxman S, Jing Y. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 1999;93(1):268-277
33. Davison K, Cote S, Mader S, Miller WH. Glutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines. Leukemia 2003;17(5):931-940
34. Yang CH, Kuo ML, Chen JC, Chen YC. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells. Br J Cancer 1999;81(5):796-799
35. Perry RR, Mazetta JA, Levin M, Barranco SC. Glutathione levels and variability in breast tumors and normal tissue. Cancer 1993;72(3):783-787
36. Gutman D, Morales AA, Croutch CR, et al. S-dimethylarsinoglutathione (ZIO-101) a novel arsenical with activtity in myeloma. Haematologica 2007;97(Suppl 2):abstract nr PO-504
37. Komarnitsky PB, Qu Z, Schwartz B, Wallner B. ZIO-101 an oral multi-targeted anti-cancer drug with anti-angiogenic activity [abstract]. American Association for Cancer Research Annual Meeting: Proceedings 2007;48:abstract nr 4000
38. Goldin A. Combined Chemotherapy. Oncology 1980;37(S1):3-8
39. Campbell RA, Sanchez E, Chen H, et al. ZIO-101, a novel organic arsenic, inhibits human myeloma cell growth in a SCID-hu model [abstract]. Blood 2006;108:abstract nr 3462
40. Kala SV, Neely MW, Kala G, et al. The MRP2/cMOAT transporter and arsenic-glutathione complex formation are required for biliary excretion of arsenic. J Biol Chem 2000;275(43):33404-33408
41. Camacho LH, Kornblau S, Berenson JR, et al. A new organic arsenic in advanced cancers. 18th EORTC-NCI-AACR Symposium of Molecular Targets and Cancer Therapeutics. Eur J Cancer Suppl 2006;4(12):146-147
42. Camacho LH, Hong DS, Guiterrez C, et al. Organic arsenic in patients with advanced solid tumors: phase-1 results of ZIO-101 (s-dimethylarseno-glutatione) . J Clin Oncol 2007;25(18s):abstract nr 3554
43. Lossos I, Craig MD, Tallman MS, et al. Novel organic arsenic molecule darinaparsin: development of IV and oral forms. J Clin Oncol 2009;27(15s):suppl abstract nr 8501
44. Wu J, Henderson C, Feun L, et al. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma. Invest New Drugs 2009 [Epub ahead of print]